دورية أكاديمية
أعرض في EDS

Trinucleotide mRNA Cap Analogue N 6-Benzylated at the Site of Posttranscriptional m6 A m Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo.

التفاصيل البيبلوغرافية
العنوان: Trinucleotide mRNA Cap Analogue N 6-Benzylated at the Site of Posttranscriptional m6 A m Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo.
المؤلفون: Warminski M; Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, 02-089 Warsaw, Poland., Trepkowska E; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Smietanski M; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Sikorski PJ; Centre of New Technologies, University of Warsaw, 02-089 Warsaw, Poland.; Laboratory of Epitranscriptomics, Department of Environmental Microbiology and Biotechnology, Institute of Microbiology, Faculty of Biology, Biological and Chemical Research Centre, University of Warsaw, 02-089 Warsaw, Poland., Baranowski MR; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Bednarczyk M; Centre of New Technologies, University of Warsaw, 02-089 Warsaw, Poland.; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Kedzierska H; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Majewski B; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Mamot A; Centre of New Technologies, University of Warsaw, 02-089 Warsaw, Poland., Papiernik D; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Popielec A; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Serwa RA; Proteomics Core Facility, IMol Polish Academy of Sciences, 02-247 Warsaw, Poland., Shimanski BA; Department of Chemistry & Biochemistry, University of Delaware, Newark, Delaware 19716, United States., Sklepkiewicz P; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Sklucka M; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Sokolowska O; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Spiewla T; Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, 02-089 Warsaw, Poland.; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Toczydlowska-Socha D; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Warminska Z; Centre of New Technologies, University of Warsaw, 02-089 Warsaw, Poland., Wolosewicz K; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Zuberek J; Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, 02-089 Warsaw, Poland., Mugridge JS; Department of Chemistry & Biochemistry, University of Delaware, Newark, Delaware 19716, United States., Nowis D; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland.; Laboratory of Experimental Medicine, Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland., Golab J; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland.; Laboratory of Experimental Medicine, Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland., Jemielity J; Centre of New Technologies, University of Warsaw, 02-089 Warsaw, Poland.; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland., Kowalska J; Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, 02-089 Warsaw, Poland.; Explorna Therapeutics sp. z o.o. Zwirki i Wigury 93, 02-089 Warsaw, Poland.
المصدر: Journal of the American Chemical Society [J Am Chem Soc] 2024 Mar 27; Vol. 146 (12), pp. 8149-8163. Date of Electronic Publication: 2024 Mar 05.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 7503056 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5126 (Electronic) Linking ISSN: 00027863 NLM ISO Abbreviation: J Am Chem Soc Subsets: MEDLINE
أسماء مطبوعة: Publication: Washington, DC : American Chemical Society
Original Publication: Easton, Pa. [etc.]
مواضيع طبية MeSH: RNA Caps*/chemistry , RNA Caps*/genetics , RNA Caps*/metabolism , Vaccines*, Animals ; Mice ; RNA, Messenger/genetics ; Protein Biosynthesis ; Methylation
مستخلص: Eukaryotic mRNAs undergo cotranscriptional 5'-end modification with a 7-methylguanosine cap. In higher eukaryotes, the cap carries additional methylations, such as m6 A m ─a common epitranscriptomic mark unique to the mRNA 5'-end. This modification is regulated by the Pcif1 methyltransferase and the FTO demethylase, but its biological function is still unknown. Here, we designed and synthesized a trinucleotide FTO-resistant N 6-benzyl analogue of the m6 A m -cap-m 7 Gppp Bn6 A m pG (termed AvantCap ) and incorporated it into mRNA using T7 polymerase. mRNAs carrying Bn6 A m showed several advantages over typical capped transcripts. The Bn6 A m moiety was shown to act as a reversed-phase high-performance liquid chromatography (RP-HPLC) purification handle, allowing the separation of capped and uncapped RNA species, and to produce transcripts with lower dsRNA content than reference caps. In some cultured cells, Bn6 A m mRNAs provided higher protein yields than mRNAs carrying A m or m6 A m , although the effect was cell-line-dependent. m 7 Gppp Bn6 A m pG-capped mRNAs encoding reporter proteins administered intravenously to mice provided up to 6-fold higher protein outputs than reference mRNAs, while mRNAs encoding tumor antigens showed superior activity in therapeutic settings as anticancer vaccines. The biochemical characterization suggests several phenomena potentially underlying the biological properties of AvantCap : (i) reduced propensity for unspecific interactions, (ii) involvement in alternative translation initiation, and (iii) subtle differences in mRNA impurity profiles or a combination of these effects. AvantCapped- mRNAs bearing the Bn6 A m may pave the way for more potent mRNA-based vaccines and therapeutics and serve as molecular tools to unravel the role of m6 A m in mRNA.
References: Bioorg Med Chem. 2023 Jan 1;77:117128. (PMID: 36516685)
Nat Commun. 2019 Dec 10;10(1):5636. (PMID: 31822664)
Top Curr Chem (Cham). 2017 Feb;375(1):16. (PMID: 28116583)
Int J Mol Sci. 2023 Jan 23;24(3):. (PMID: 36768600)
Nucleic Acids Symp Ser (Oxf). 2009;(53):129-30. (PMID: 19749294)
Mol Cell. 2018 Sep 20;71(6):973-985.e5. (PMID: 30197295)
Curr Protoc. 2021 Feb;1(2):e39. (PMID: 33524237)
EMBO J. 2023 Jan 16;42(2):e111673. (PMID: 36514940)
J Biol Chem. 1981 Oct 10;256(19):10054-60. (PMID: 7275966)
Open Biol. 2020 Feb;10(2):190306. (PMID: 32097574)
Angew Chem Int Ed Engl. 2023 Jan 23;62(4):e202211957. (PMID: 36282111)
Mol Ther. 2008 Nov;16(11):1833-40. (PMID: 18797453)
Nat Commun. 2021 Aug 6;12(1):4778. (PMID: 34362929)
Nat Commun. 2023 May 11;14(1):2657. (PMID: 37169757)
Cell Res. 2019 Jan;29(1):80-82. (PMID: 30487554)
Chem Sci. 2023 Sep 18;14(39):10962-10970. (PMID: 37829022)
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):. (PMID: 34266951)
Angew Chem Int Ed Engl. 2021 Jun 7;60(24):13280-13286. (PMID: 33751748)
Pharmaceutics. 2021 Nov 16;13(11):. (PMID: 34834356)
Mol Cell. 2019 May 16;74(4):640-650. (PMID: 31100245)
Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549)
RNA. 2023 Feb;29(2):200-216. (PMID: 36418172)
Nature. 2020 Oct;586(7830):594-599. (PMID: 32998157)
J Chromatogr A. 2023 Sep 27;1707:464321. (PMID: 37639849)
Methods Mol Biol. 2013;969:43-54. (PMID: 23296926)
Nucleic Acids Res. 2004 Jan 15;32(1):e14. (PMID: 14744982)
Sci Rep. 2011;1:126. (PMID: 22355643)
Bioessays. 2023 Mar;45(3):e2200198. (PMID: 36529693)
Science. 2020 Nov 13;370(6518):853-856. (PMID: 33184215)
J Am Chem Soc. 2015 Feb 11;137(5):2107-15. (PMID: 25611135)
Cell Rep. 2020 Aug 18;32(7):108038. (PMID: 32814042)
Nat Rev Drug Discov. 2014 Oct;13(10):759-80. (PMID: 25233993)
Nat Commun. 2018 Aug 3;9(1):3068. (PMID: 30076308)
J Org Chem. 2022 Aug 5;87(15):10333-10348. (PMID: 35857285)
J Mol Biol. 2007 Sep 7;372(1):7-15. (PMID: 17631896)
Nat Commun. 2021 Dec 10;12(1):7185. (PMID: 34893620)
Nucleic Acids Res. 2022 Jan 11;50(1):e3. (PMID: 34591964)
Nat Struct Mol Biol. 2016 Nov;23(11):987-994. (PMID: 27694842)
RNA. 1995 Nov;1(9):957-67. (PMID: 8548660)
Proc Natl Acad Sci U S A. 1975 Feb;72(2):742-5. (PMID: 1054852)
Mol Cell. 2019 Aug 8;75(3):631-643.e8. (PMID: 31279658)
Eur J Med Chem. 2010 Apr;45(4):1304-13. (PMID: 20060622)
Nucleic Acids Res. 2011 Jun;39(11):4756-68. (PMID: 21310715)
Nucleic Acids Res. 2020 Feb 28;48(4):1607-1626. (PMID: 31984425)
Nucleic Acids Res. 2022 Sep 9;50(16):9051-9071. (PMID: 36018811)
Nat Commun. 2014;5:3004. (PMID: 24402442)
Mol Cell. 2019 Aug 8;75(3):620-630.e9. (PMID: 31279659)
Nat Rev Cancer. 2023 Aug;23(8):526-543. (PMID: 37311817)
Nucleic Acids Res. 2003 Aug 1;31(15):4472-80. (PMID: 12888507)
J Am Chem Soc. 2019 Dec 26;141(51):19988-19993. (PMID: 31826614)
Nature. 2017 Jan 19;541(7637):371-375. (PMID: 28002401)
Front Mol Biosci. 2022 Aug 19;9:854170. (PMID: 36060251)
Nat Commun. 2021 Nov 30;12(1):6979. (PMID: 34848685)
RNA. 2004 Sep;10(9):1479-87. (PMID: 15317978)
Cell Rep. 2023 Aug 29;42(8):112868. (PMID: 37494188)
Nat Commun. 2021 Sep 20;12(1):5543. (PMID: 34545078)
RSC Adv. 2023 Apr 25;13(19):12809-12824. (PMID: 37114020)
Nature. 1975 Sep 18;257(5523):251-3. (PMID: 1161029)
Nature. 2012 Apr 29;485(7397):201-6. (PMID: 22575960)
Science. 2019 Jan 11;363(6423):. (PMID: 30467178)
Cell. 2012 Jun 22;149(7):1635-46. (PMID: 22608085)
Nat Rev Cancer. 2014 Feb;14(2):135-46. (PMID: 24457417)
J Control Release. 2015 Nov 10;217:337-44. (PMID: 26342664)
Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2210361120. (PMID: 36689652)
Nature. 2023 Feb;614(7947):358-366. (PMID: 36725932)
J Biol Chem. 2010 Oct 22;285(43):33037-33044. (PMID: 20713356)
Nucleic Acids Res. 2019 Nov 18;47(20):e130. (PMID: 31504804)
Nature. 2011 May 19;473(7347):337-42. (PMID: 21593866)
Nature. 2016 Aug 4;536(7614):96-9. (PMID: 27462815)
Acc Chem Res. 2022 May 3;55(9):1249-1261. (PMID: 35420432)
Mass Spectrom Rev. 2023 Jul 4;:. (PMID: 37401740)
J Biol Chem. 1978 Jul 25;253(14):5033-9. (PMID: 670176)
Acc Chem Res. 2023 Oct 17;56(20):2814-2826. (PMID: 37782471)
Annu Rev Cell Dev Biol. 2017 Oct 6;33:319-342. (PMID: 28759256)
Chemistry. 2021 Aug 19;27(47):12190-12197. (PMID: 34114681)
معلومات مُعتمدة: R35 GM143000 United States GM NIGMS NIH HHS; T32 GM133395 United States GM NIGMS NIH HHS
المشرفين على المادة: 0 (RNA, Messenger)
0 (RNA Caps)
0 (Vaccines)
تواريخ الأحداث: Date Created: 20240305 Date Completed: 20240328 Latest Revision: 20240710
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC10979456
DOI: 10.1021/jacs.3c12629
PMID: 38442005
قاعدة البيانات: MEDLINE
الوصف
تدمد:1520-5126
DOI:10.1021/jacs.3c12629